View Your Favorites

    Access your saved content with one easy click.

    My Favorites

    Save Your Favorites

    Subscribe for free to save your favorites and view a personalized view of content.

    Subscribe for Free

    Be a Contributor

    Submit new content suggestions for Condensates.com.

    Contribute

Condensate News: First c-mod enters the clinic with special FDA designations

The first drug intentionally discovered, optimized and developed using a condensate lens enters the clinic. Dewpoint Therapeutics’ DPTX3186 is an orally-available condensate modulator (c-mod) that inhibits the oncogenic function of beta catenin by trapping it into transcriptionally-inactive condensates. DPTX3816 cleared IND in October 2025, and was granted Orphan Drug and Fast Track designations by the FDA. Clinical trials 1a/2a are expected to start in December 2025, targeting gastric cancer as the therapeutic indication.

 

Read more in the following The Pharma Letter articles:

Dewpoint doubles up on major milestones with oral small-molecule condensate modulator 

Fast Track Designation for Dewpoint’s gastric cancer candidate